Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The FDA says new labels will make it easier to spot harmful ingredients. A UVA nutritionist suggests taking a holistic ...

Fitness and nutrition gurus like to make weight loss sound easy. But in reality, it’s often incredibly tough to incorporate ...

This is an emergency, Conner said. About 50% of people who have an aortic dissection die at home. Of the other 50% who make ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Erectile Dysfunction Drugs Market 2025 The global market is driven by factors such as an Increase in the prevalence of erectile dysfunction ...

President and Chief Medical Officer, Dr. Joseph Varon, released the following statement today on the Senate Finance Committee ...

Thomas Oide/Axios A slew of advertisers are bringing a healthier and more female-focused message to this year's big game, with spots highlighting everything from breast cancer awareness to obesity and ...

Also in today’s newsletter, Microsoft poaches DeepMind staff behind AI podcasting feature, and FBI agents sue Trump ...

Q4 2024 Earnings Call Feb 04, 2025, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants.

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...